Novo Nordisk's Wegovy high-dose data shows robust efficacy, but pricing and share loss remain overhangs.

What happened

Novo Nordisk presented sub-analyses from the STEP UP trial at the European Congress on Obesity, showing that a higher dose of Wegovy helped patients achieve substantial weight loss and fat reduction regardless of how quickly they initially responded to treatment. While this reinforces the drug's clinical profile, the company's 2026 filings already acknowledge it has lost US weekly prescription leadership and volume market share in GLP-1 obesity and diabetes amid intensifying competition from Eli Lilly. The master report flags that US net pricing is under unprecedented pressure, with self-pay subscription pricing anchored at $249–$399/month and a looming Medicare price negotiation in 2027. The new data does not address these commercial headwinds, and the stock's 12.4x P/E already discounts a structurally lower net-price regime. Near-term reported sales will also be distorted by a one-time $4.2B 340B revenue recognition, making it difficult to underwrite normalized underlying trends.

Implication

The STEP UP sub-analyses are clinically supportive but commercially irrelevant to the dominant investment debate—Novo's ability to defend US net price and stabilize volume share against Lilly's competitive pressure. The stock's current valuation embeds a sustained net-price squeeze, and without evidence that telehealth distribution and oral semaglutide can reverse share losses, the risk-reward remains unattractive. Investors should monitor upcoming Q1 2026 filings for a transparent revenue bridge that isolates the $4.2B 340B recognition and for early Wegovy Pill commercialization metrics. Until filings show that self-pay pricing bands are holding and share losses are stabilizing, the thesis remains wait-and-see with a re-assessment window of 3–6 months.

Thesis delta

No material shift. The new data confirms Wegovy's efficacy but does not alter the core thesis that US pricing pressure and competitive share loss are the dominant variables. The clinical win is marginal against the commercial headwinds already embedded in the WAIT rating.